Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) filed a Current Report on Form 8-K dated December 12, 2022. The filing details significant capital raising activities, including a registered direct offering of equity and the execution of a new related-party promissory note, alongside the conversion of an existing debt instrument.
Key Financial Metrics and Capital Structure
- Equity Financing: Agreed to sell 9,090,909 shares of common stock and warrants to purchase an additional 9,090,909 shares at an exercise price of $6.60. The purchase price was $5.50 per share and warrant, generating gross proceeds of approximately $50.0 million.
- Debt Financing: Executed a new $50.0 million variable-rate promissory note with Nant Capital, LLC (affiliated with Executive Chairman Dr. Patrick Soon-Shiong). The note bears interest at Term SOFR plus 8.0% per annum, with principal and interest due on December 31, 2023.
- Debt Conversion: Received notice of the full conversion of an existing convertible promissory note held by NantWorks, LLC. The outstanding principal and accrued interest of approximately $56.6 million will be converted into common stock at $5.67 per share.
- Liquidity Position: Pro forma cash, cash equivalents, and marketable securities as of November 30, 2022, are estimated at approximately $160.0 million (including $155.1 million in cash/cash equivalents and $4.9 million in marketable securities) after accounting for net proceeds of approximately $96.4 million from the equity and debt financings.
- Placement Fees: Piper Sandler & Co. was engaged as the exclusive placement agent for a cash fee equal to 6.0% of the gross proceeds from the equity sale.
Material Changes and Transactions
The filing reports a material increase in liquidity through the simultaneous execution of equity and debt instruments. The company reduced its existing "at-the-market" offering size to $238,795,982 to accommodate the new registered direct offering. Additionally, the company eliminated approximately $56.6 million in outstanding debt through the conversion of the NantWorks note into equity, altering its capital structure by increasing share count while reducing debt obligations.
Outlook, Management Commentary, and Risks
- Use of Proceeds: The company intends to use the approximately $96.4 million in net proceeds for pre-commercialization efforts, clinical development programs, other research and development activities, capital expenditures, and general corporate purposes.
- Debt Prepayment Conditions: The new $50.0 million note with Nant Capital requires mandatory prepayment of principal and accrued interest if the company successfully closes a strategic collaboration transaction with a large biopharmaceutical company.
- Financial Estimates: The reported liquidity figures are preliminary estimates based on information available as of the filing date. Actual amounts reported in the Form 10-K for the year ended December 31, 2022, may differ materially due to final financial closing procedures.
Investor Verification Checklist
- Verify the final closing date of the registered direct offering and the exact net proceeds after all fees and expenses.
- Confirm the final share count resulting from the conversion of the $56.6 million NantWorks note.
- Monitor the interest rate fluctuations on the new $50.0 million note based on Term SOFR.
- Review the upcoming Form 10-K for finalized cash balances and any adjustments to the preliminary $160.0 million liquidity estimate.
- Assess the dilution impact of the new shares issued in the direct offering and the warrant exercise potential.